EV-out or EV-in: Tackling cell-to-cell communication within the tumor microenvironment to enhance anti-tumor efficacy using extracellular vesicle-based therapeutic strategies

Chiangjong, Wararat

doi:10.1016/j.onano.2022.100085

Cited by 8 publications

(5 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, less is known regarding the role of extracellular vesicles in this scenario [30]. Indeed, EVs contain many signals and molecules that support the inactivation or hyperactivation of some components of innate immunity that accelerate tumor growth [31]. The anti-cancer immune response is the body's first barrier against the onset of cancer and refers to the body's natural defense mechanisms that help in the recognition and elimination of cancer cells [32].…”

Section: Discussionmentioning

confidence: 99%

Influence of Breast Cancer Extracellular Vesicles on Immune Cell Activation: A Pilot Study

Santoro,

Carrese,

Peluso

et al. 2023

Biology

View full text Add to dashboard Cite

Breast cancer is the leading cause of cancer-related death in women worldwide. It is well known that breast cancer shows significant alterations in the tumor microenvironment (TME), which is composed of a variety of immune cells, including natural killer (NK) cells, that have a key role in tumor development or anti-tumor responses in breast cancer patients. Luminal B (BT474) and triple-negative breast cancer (HS578T) cell lines were cultured in 2D and 3D model systems. PMBCs from healthy donors were isolated and treated with extracellular vesicles (EVs) from monolayer and spheroids of BT474 and HS578T and analyzed using cytofluorimetric approaches. We observed that EVs can alter the activation and presence of CD335+/CD11b+ NK cells. EVs derived from BT474 and HS578T cells trigger the activation and, simultaneously, a reduction in the percentage of CD335+/CD11b+ NK cells. In addition, EVs derived from BT474 also significantly reduce CD39+ T-regulatory (T-reg) cells. Our preliminary data suggest that using EVs to treat tumors could potentially alter components of the immune system, which causes hyperactivation of specific cell types and can lead to aggressive growth. These data will guide the designing of new personalized diagnostic approaches based on in-depth study of the TME.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of Breast Cancer Extracellular Vesicles on Immune Cell Activation: A Pilot Study

Santoro,

Carrese,

Peluso

et al. 2023

Biology

View full text Add to dashboard Cite

show abstract

“…New treatment modalities are needed. Herein, a novel EV-in treatment strategy [46] is proposed to utilize RBC-EV miR-204 as a new mode of adjunct therapy against high-risk neuroblastoma.…”

Section: Discussionmentioning

confidence: 99%

Red blood cell-derived extracellular vesicles with miR-204 mimic loading for pediatric neuroblastoma treatment

Chiangjong

Panachan

Keadsanti

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most common extracranial solid tumor in pediatric population with a high degree of heterogeneity in clinical outcomes, ranging from spontaneous remission to rapid progression and death. Upregulation of a tumor suppressor miR-204 in patient-derived neuroblastoma tumors was associated with good prognosis independent of known risk factors. While miR-204 is recognized as a therapeutic candidate, its delivery was unavailable. This study aimed to develop red blood cell-derived extracellular vesicles (RBC-EVs) as the miR-204 carrier and evaluate the inhibitory activity against neuroblastoma cell lines and spheroids. MiR-204 mimics were loaded into RBC-EVs (RBC-EVmiR-204) by electroporation with the optimized parameters of 250 V, 20 ms, 10 pulsing times. RBC-EVmiR-204, but not the native RBC-EVs, could inhibit cell viability, migration and spheroid formation and growth of MYCN-amp and MYCN non-amplification (MYCN-NA) NB cells, even though the suppressive effects were more preferable in MYCN-amp NB. For the mechanistic insight, SWATH-proteomics suggested that RBC-EVmiR-204induced dysregulation of ribosomal proteins and alterations in RNA metabolism, leading to inhibiting neuroblastoma progression. This study developed RBC-EVmiR-204as an alternative/adjunct therapy of pediatric neuroblastoma. The therapeutic efficacy of RBC-EVmiR-204should be further investigated in preclinical models and clinical studies.

show abstract

“…Last but not least, several drugs are known to modulate the EV release and cargo contents, and thus are actively investigated to harness EV-modulated therapeutic effects against non-communicable and infectious diseases [ 183 , 184 , 185 ]. Among these medications, antiplatelets are commonly used during pregnancy.…”

Section: Placenta-derived Evs As Hb Bart’s Liquid Biopsy: Challenges ...mentioning

confidence: 99%

Placenta-Derived Extracellular Vesicles in Pregnancy Complications and Prospects on a Liquid Biopsy for Hemoglobin Bart’s Disease

Chaemsaithong

Luewan

Taweevisit

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are nano-scaled vesicles released from all cell types into extracellular fluids and specifically contain signature molecules of the original cells and tissues, including the placenta. Placenta-derived EVs can be detected in maternal circulation at as early as six weeks of gestation, and their release can be triggered by the oxygen level and glucose concentration. Placental-associated complications such as preeclampsia, fetal growth restriction, and gestational diabetes have alterations in placenta-derived EVs in maternal plasma, and this can be used as a liquid biopsy for the diagnosis, prediction, and monitoring of such pregnancy complications. Alpha-thalassemia major (“homozygous alpha-thalassemia-1”) or hemoglobin Bart’s disease is the most severe form of thalassemia disease, and this condition is lethal for the fetus. Women with Bart’s hydrops fetalis demonstrate signs of placental hypoxia and placentomegaly, thereby placenta-derived EVs provide an opportunity for a non-invasive liquid biopsy of this lethal condition. In this article, we introduced clinical features and current diagnostic markers of Bart’s hydrops fetalis, extensively summarize the characteristics and biology of placenta-derived EVs, and discuss the challenges and opportunities of placenta-derived EVs as part of diagnostic tests for placental complications focusing on Bart’s hydrop fetalis.

show abstract

EV-out or EV-in: Tackling cell-to-cell communication within the tumor microenvironment to enhance anti-tumor efficacy using extracellular vesicle-based therapeutic strategies

Cited by 8 publications

References 119 publications

Influence of Breast Cancer Extracellular Vesicles on Immune Cell Activation: A Pilot Study

Influence of Breast Cancer Extracellular Vesicles on Immune Cell Activation: A Pilot Study

Red blood cell-derived extracellular vesicles with miR-204 mimic loading for pediatric neuroblastoma treatment

Placenta-Derived Extracellular Vesicles in Pregnancy Complications and Prospects on a Liquid Biopsy for Hemoglobin Bart’s Disease

Contact Info

Product

Resources

About